Effects of Rimonabant on Walking Abilities in Incomplete Spinal Cord Injury
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
Randomized placebo-controlled safety and feasibility study with crossover design (3 arms).
Placebo or Rimonabant 2.5mg or Rimonabant 5mg will be administered for 5 days. Exploratory
efficacy will be tested using six-min walking test.